Switching to a rilpivirine/emtricitabine/tenofovir single ‐tablet regimen in RNA‐suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks

ConclusionsIn virologically suppressed patients, the switch to a RPV/FTC/TDF regimen was associated with a mild but maintained improvement in lipid parameters and a significant reduction in costs. However, the relatively high rates of virological failure and treatment discontinuation because of adverse events make this combination a less favourable choice over other regimens currently available.

Source: International Journal of Clinical Practice - June 1, 2017 Category: Internal Medicine Authors: Paula Arrabal ‐Durán, Carmen G Rodríguez‐González, Esther Chamorro‐de‐Vega, Paloma Gijón‐Vidaurreta, Ana Herranz‐Alonso, María Sanjurjo‐Sáez Tags: Original Paper Source Type: research